Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma DURHAM, NC, November 30, 2020 – Istari Oncology, Inc., a clinical-stage biotechnology company, today announced the…
From the office of University Hospitals Seidman Cancer Center: UH Seidman Cancer Center Opens New Trial with PVSRIPO, a Viral-based Immunotherapy in Combination with Pembrolizumab for Patients with Recurrent GBM The two therapies may be able to generate a potent…
Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma Phase 2 clinical study expected to begin in First Quarter 2021 DURHAM, NC, November 16, 2020 –…
For the full poster on the Phase 1 trial click the button below.
Journal authors for the below study: Mubeen M. Mosaheb, Elena Y. Dobrikova, Michael C. Brown, Yuanfan Yang , Jana Cable, Hideho Okada, Smita K. Nair, Darell D. Bigner, David M. Ashley & Matthias Gromeier Viruses naturally engage innate immunity, induce…
Journal authors for the below study: Jonathan P. Kastan, Elena Y. Dobrikova, Jeffrey D. Bryant, Matthias Gromeier Cells respond to environmental stress with coordinated transcriptional, translational, and posttranslational gene expression changes. The pivotal event in the integrated stress response (ISR)…
Welcome to our new website; we invite you to look around. Please contact us if you have questions about our PVS-RIPO or ADC immunotherapy technologies for cancer treatment. You may also sign up to be automatically notified by email any…
21% Overall Survival at 24 Months and 36 Months, Compared to 14% and 4% in Matched Historical Controls PVSRIPO Granted Breakthrough Status and Orphan Status from the US Food and Drug Administration (FDA) in Glioblastoma Multi-Center Phase 2 Trial Currently…